| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 20.296 | 22.069 | 20.889 | 17.248 | 19.360 | 14.276 | 16.835 | 19.069 | 12.654 | 9.420 |
| Total Income - EUR | 21.180 | 22.069 | 20.889 | 17.248 | 19.360 | 14.276 | 16.835 | 19.069 | 12.654 | 9.621 |
| Total Expenses - EUR | 4.933 | 4.332 | 5.330 | 9.013 | 8.793 | 7.492 | 6.870 | 4.807 | 5.546 | 3.949 |
| Gross Profit/Loss - EUR | 16.248 | 17.737 | 15.559 | 8.235 | 10.566 | 6.784 | 9.965 | 14.262 | 7.109 | 5.672 |
| Net Profit/Loss - EUR | 15.612 | 17.075 | 14.932 | 7.717 | 9.985 | 6.387 | 9.470 | 13.730 | 5.777 | 4.642 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Gineobimed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.791 | 1.662 | 20.081 | 14.906 | 9.961 | 5.205 | 1.368 | 1.373 | -1 | 0 |
| Current Assets | 28.988 | 20.858 | 7.147 | 23.543 | 10.745 | 8.726 | 9.233 | 22.245 | 7.904 | 6.109 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 6.252 | 1.880 | 3.742 | 976 | 975 | 716 | 1.012 | 10.315 | 2.426 | 0 |
| Cash | 22.736 | 18.978 | 3.405 | 22.567 | 9.770 | 8.010 | 8.220 | 11.930 | 5.478 | 6.109 |
| Shareholders Funds | 29.222 | 17.274 | 15.276 | 22.713 | 11.186 | 10.615 | 9.423 | 13.684 | 5.922 | 4.802 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 1.617 | 5.247 | 11.952 | 15.735 | 9.521 | 3.316 | 1.178 | 9.933 | 1.981 | 1.307 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Gineobimed S.r.l.